Emerging drugs for the treatment of metastatic renal cancer

Related Experiment Video

Updated: Jul 10, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Wolfram E Samlowski1, Nicholas J Vogelzang

  • 1Section of Melanoma, Renal Cancer and Immunotherapy Nevada Cancer Institute, One Breakthrough Way, Las Vegas, NV 89135, USA. wsamlowski@nvcancer.org

Expert Opinion on Emerging Drugs
|November 6, 2007
PubMed

Insights

New targeted therapies have emerged for metastatic renal cancer, offering improved treatment options beyond traditional immunotherapy. Research focuses on blocking key pathways like vascular endothelial growth factor and mTOR.

Area of Science:

  • Oncology
  • Cancer Biology
  • Pharmacology

Background:

  • Metastatic renal cancer treatment options were historically limited and largely ineffective.
  • Immunotherapy agents like interferon-alpha (IFN-alpha) and interleukin-2 (IL-2) were primary treatments.
  • Recent advances identified key signaling pathways regulating tumor growth.

Purpose of the Study:

  • To review the current status of novel therapeutic agents for renal cancer.
  • To highlight recent drug approvals and ongoing clinical trials.
  • To anticipate future research directions in renal cancer treatment.

Main Methods:

  • Review of recent scientific literature and clinical trial data.
  • Identification of targeted therapies based on cancer biology insights.
  • Analysis of approved agents and investigational molecules.

Main Results:

  • Four new agents (bevacizumab, sorafenib, sunitinib, temsirolimus) approved since 2004.
  • Identification of numerous novel agents targeting vascular endothelial growth factor and mTOR pathways.
  • These agents are progressing rapidly in clinical trials for renal cancer and other malignancies.

Conclusions:

  • Significant progress has been made in developing targeted therapies for renal cancer.
  • The landscape of renal cancer treatment is rapidly evolving with new molecularly targeted agents.
  • Future research will likely focus on further refining these targeted approaches and exploring combination therapies.

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...